<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33021723</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>308</EndPage><MedlinePgn>297-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-020-00933-3</ELocationID><Abstract><AbstractText>In amyotrophic lateral sclerosis (ALS), motor neuron degeneration occurs simultaneously with systemic metabolic dysfunction and neuro-inflammation. The fibroblast growth factor 21 (FGF21) plays an important role in the regulation of both phenomena and is a major hormone of energetic homeostasis. In this study, we aimed to determine the relevance of FGF21 pathway stimulation in a male mouse model of ALS (mutated SOD1-G93A mice) by using a pharmacological agonist of FGF21, R1Mab1. Mice (SOD1-WT and mutant SOD1-G93A) were treated with R1Mab1 or vehicle. Longitudinal data about clinical status (motor function, body weight) and biological parameters (including hormonal, immunological, and metabolomics profiles) were collected from the first symptoms to euthanasia at week 20. Multivariate models were performed to identify the main parameters associated with R1Mab1 treatment and to link them with clinical status, and metabolic pathways involving the discriminant metabolites were also determined. A beneficial clinical effect of R1Mab1 was revealed on slow rotarod (p&#x2009;=&#x2009;0.032), despite a significant decrease in body weight of ALS mice (p&#x2009;&lt;&#x2009;0.001). We observed a decrease in serum TNF-&#x3b1;, MCP-1, and insulin levels (p&#x2009;=&#x2009;0.0059, p&#x2009;=&#x2009;0.003, and p&#x2009;=&#x2009;0.01, respectively). At 16&#xa0;weeks, metabolomics analyses revealed a clear discrimination (CV-ANOVA&#x2009;=&#x2009;0.0086) according to the treatment and the most discriminant pathways, including sphingolipid metabolism, butanoate metabolism, pantothenate and CoA biosynthesis, and the metabolism of amino acids like tyrosine, arginine, proline, glycine, serine, alanine, aspartate, and glutamate. Mice treated with R1Mab1 had mildly higher performance on slow rotarod despite a decrease on body weight and could be linked with the anti-inflammatory effect of R1Mab1. These results indicate that FGF21 pathway is an interesting target in ALS, with a slight improvement in motor function combined with metabolic and anti-inflammatory effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delaye</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et de Biologie Mol&#xe9;culaire, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 2 Bd Tonnell&#xe9;, 37044, Tours Cedex, France. j.delaye@chu-tours.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanznaster</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veyrat-Durebex</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et de Biologie Mol&#xe9;culaire, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 2 Bd Tonnell&#xe9;, 37044, Tours Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service d'anatomie et cytologie pathologique, Centre Hospitalier R&#xe9;gional Universitaire de Tours, h&#xf4;pital Bretonneau, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacle</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de chirurgie orthop&#xe9;dique, Centre Hospitalier R&#xe9;gional Universitaire de Tours, h&#xf4;pital Trousseau, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefevre</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hergesheimer</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecron</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Laboratoire Inflammation, Tissus Epith&#xe9;liaux et Cytokines Universit&#xe9; de Poitiers Equipe d'acceuil 4331, 86073, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et de Biologie Mol&#xe9;culaire, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 2 Bd Tonnell&#xe9;, 37044, Tours Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>C R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et de Biologie Mol&#xe9;culaire, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 2 Bd Tonnell&#xe9;, 37044, Tours Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maillot</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de m&#xe9;decine interne, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre SLA, Service de Neurologie, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emond</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de M&#xe9;decine Nucl&#xe9;aire in vitro, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 37044, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et de Biologie Mol&#xe9;culaire, Centre Hospitalier R&#xe9;gional Universitaire de Tours, 2 Bd Tonnell&#xe9;, 37044, Tours Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; mixte de recherche 1253, iBrain, University of Tours, Inserm, 37044, Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491768">Ccl2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020738">Leptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052243">Resistin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C414620">fibroblast growth factor 21</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018932" MajorTopicYN="N">Chemokine CCL2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020738" MajorTopicYN="N">Leptin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052243" MajorTopicYN="N">Resistin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045442" MajorTopicYN="N">Rotarod Performance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">FGF21</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">R1Mab1</Keyword><Keyword MajorTopicYN="N">SODG93A</Keyword><Keyword MajorTopicYN="N">Therapeutic antibody</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33021723</ArticleId><ArticleId IdType="pmc">PMC8116478</ArticleId><ArticleId IdType="doi">10.1007/s13311-020-00933-3</ArticleId><ArticleId IdType="pii">10.1007/s13311-020-00933-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat P-F, Ludolph AC, Loeffler J-P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:23&#x2013;9. doi: 10.1080/146608202317576507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608202317576507</ArticleId><ArticleId IdType="pubmed">12061945</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano O, Beers DR, Henkel JS, Appel SH. Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology. 2012;78:833&#x2013;835. doi: 10.1212/WNL.0b013e318249f776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318249f776</ArticleId><ArticleId IdType="pmc">PMC3304948</ArticleId><ArticleId IdType="pubmed">22377817</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, Feldman EL. The dual roles of immunity in ALS: injury overrides protection. Neurobiol Dis. 2015;77:1&#x2013;12. doi: 10.1016/j.nbd.2015.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.017</ArticleId><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Di&#xe9;m&#xe9; B, Mavel S, Blasco H, et al. Metabolomics study of urine in autism spectrum disorders using a multiplatform analytical methodology. J Proteome Res. 2015;14:5273&#x2013;5282. doi: 10.1021/acs.jproteome.5b00699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b00699</ArticleId><ArticleId IdType="pubmed">26538324</ArticleId></ArticleIdList></Reference><Reference><Citation>Madji Hounoum B, Blasco H, Nadal-Desbarats L, et al. Analytical methodology for metabolomics study of adherent mammalian cells using NMR, GC-MS and LC-HRMS. Anal Bioanal Chem. 2015;407:8861&#x2013;8872. doi: 10.1007/s00216-015-9047-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-015-9047-x</ArticleId><ArticleId IdType="pubmed">26446897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Li H, Zhao Y, et al. Saponins from stems and leaves of Panax ginseng prevent obesity via regulating thermogenesis, lipogenesis and lipolysis in high-fat diet-induced obese C57BL/6 mice. Food Chem Toxicol. 2017;106:393&#x2013;403. doi: 10.1016/j.fct.2017.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2017.06.012</ArticleId><ArticleId IdType="pubmed">28599882</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS&#xae; models. J Chemometr. 2008;22:594&#x2013;600. doi: 10.1002/cem.1187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cem.1187</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008;36:D480&#x2013;D484. doi: 10.1093/nar/gkm882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkm882</ArticleId><ArticleId IdType="pmc">PMC2238879</ArticleId><ArticleId IdType="pubmed">18077471</ArticleId></ArticleIdList></Reference><Reference><Citation>Assenov Y, Ram&#xed;rez F, Schelhorn S-E, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008;24:282&#x2013;284. doi: 10.1093/bioinformatics/btm554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btm554</ArticleId><ArticleId IdType="pubmed">18006545</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformatics. 2016;55:14.10.1&#x2013;14.10.91. doi: 10.1002/cpbi.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpbi.11</ArticleId><ArticleId IdType="pubmed">27603023</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol. 1994;145:1271&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887498</ArticleId><ArticleId IdType="pubmed">7992831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A-L, Kolumam G, Stawicki S, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med. 2011;3:113ra126. doi: 10.1126/scitranslmed.3002669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002669</ArticleId><ArticleId IdType="pubmed">22174314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A-L, Feng B, Chen MZ, et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS One 2013;8. 10.1371/journal.pone.0057322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3579827</ArticleId><ArticleId IdType="pubmed">23451204</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018&#x2013;6027. doi: 10.1210/en.2008-0816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2008-0816</ArticleId><ArticleId IdType="pubmed">18687777</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, Nagaoka U, Nakayama Y, et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler. 2012;13:363&#x2013;366. doi: 10.3109/17482968.2012.678366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.678366</ArticleId><ArticleId IdType="pubmed">22632442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 2010;11:206&#x2013;212. doi: 10.1016/j.cmet.2010.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2010.02.001</ArticleId><ArticleId IdType="pmc">PMC2847690</ArticleId><ArticleId IdType="pubmed">20197053</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuevas-Ramos D, Aguilar-Salinas CA. Modulation of energy balance by fibroblast growth factor 21. Horm Mol Biol Clin Invest 2017;30. 10.1515/hmbci-2016-0023.</Citation><ArticleIdList><ArticleId IdType="pubmed">27318658</ArticleId></ArticleIdList></Reference><Reference><Citation>Peixoto PM, Kim H-J, Sider B, Starkov A, Horvath TL, Manfredi G. UCP2 overexpression worsens mitochondrial dysfunction and accelerates disease progression in a mouse model of amyotrophic lateral sclerosis. Mol Cell Neurosci. 2013;57:104. doi: 10.1016/j.mcn.2013.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.10.002</ArticleId><ArticleId IdType="pmc">PMC3891658</ArticleId><ArticleId IdType="pubmed">24141050</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, di Scala F, Rene F, et al. Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J. 2003;17:2091&#x2013;2093. doi: 10.1096/fj.02-1182fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-1182fje</ArticleId><ArticleId IdType="pubmed">14500553</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J-P, Picchiarelli G, Dupuis L, Gonzalez de Aguilar J-L. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol 2016. 10.1111/bpa.12350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervishi I, Gozutok O, Murnan K, et al. Protein-protein interactions reveal key canonical pathways, upstream regulators, interactome domains, and novel targets in ALS. Sci Rep 2018;8. 10.1038/s41598-018-32902-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6170493</ArticleId><ArticleId IdType="pubmed">30283000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutchak PA, Katafuchi T, Bookout AL, et al. Fibroblast growth factor-21 regulates PPAR&#x3b3; activity and the antidiabetic actions of thiazolidinediones. Cell. 2012;148:556&#x2013;67. doi: 10.1016/j.cell.2011.11.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.11.062</ArticleId><ArticleId IdType="pmc">PMC3273727</ArticleId><ArticleId IdType="pubmed">22304921</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wang Y, Hou L, Xiong Y, Zhao S. Fibroblast growth factor 21 (FGF21) promotes formation of aerobic myofibers via the FGF21-SIRT1-AMPK-PGC1&#x3b1; pathway. J Cell Physiol 2016. 10.1002/jcp.25735.</Citation><ArticleIdList><ArticleId IdType="pubmed">27966786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin X-Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep 2017;7. 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlam L, Piepers S, Sutedja NA, et al. Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study. J Neurol 2015. 10.1007/s00415-014-7612-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25549972</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, He J, Li S, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-&#x3ba;B signaling pathway. Int Immunopharmacol. 2016;38:144&#x2013;52. doi: 10.1016/j.intimp.2016.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2016.05.026</ArticleId><ArticleId IdType="pubmed">27276443</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabacka M, Pierzchalska M, Dean M, Reiss K. Regulation of ketone body metabolism and the role of PPAR&#x3b1;. Int J Mol Sci 2016;17. 10.3390/ijms17122093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187893</ArticleId><ArticleId IdType="pubmed">27983603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, de Aguilar J-LG, Loeffler J-P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101:11159&#x2013;64. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus P, Fayemendy P, Nicol M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018;25:97&#x2013;104. doi: 10.1111/ene.13468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17:790&#x2013;797. doi: 10.1016/j.cmet.2013.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.03.019</ArticleId><ArticleId IdType="pmc">PMC3667496</ArticleId><ArticleId IdType="pubmed">23663742</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Lange DJ, Voustianiouk A, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci 2006;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1488864</ArticleId><ArticleId IdType="pubmed">16584562</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, Wong Y, Barkl-Luke ME, et al. Triheptanoin protects motor neurons and delays the onset of motor symptoms in a mouse model of amyotrophic lateral sclerosis. PLoS One 2016;11. 10.1371/journal.pone.0161816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001695</ArticleId><ArticleId IdType="pubmed">27564703</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco V, Longone P, Spalloni A, Pieroni L, Urbani A. Crosstalk between oxidative stress and mitochondrial damage: focus on amyotrophic lateral sclerosis. Adv Exp Med Biol. 2019;1158:71&#x2013;82. doi: 10.1007/978-981-13-8367-0_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-13-8367-0_5</ArticleId><ArticleId IdType="pubmed">31452136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalhan SC, Hanson RW. Resurgence of serine: an often neglected but indispensable amino acid. J Biol Chem. 2012;287:19786&#x2013;19791. doi: 10.1074/jbc.R112.357194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R112.357194</ArticleId><ArticleId IdType="pmc">PMC3370164</ArticleId><ArticleId IdType="pubmed">22566694</ArticleId></ArticleIdList></Reference><Reference><Citation>di Salvo ML, Contestabile R, Paiardini A, Maras B. Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. Med Hypotheses. 2013;80:633&#x2013;636. doi: 10.1016/j.mehy.2013.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2013.02.008</ArticleId><ArticleId IdType="pubmed">23474074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10:723&#x2013;736. doi: 10.1038/nrendo.2014.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2014.171</ArticleId><ArticleId IdType="pmc">PMC4424797</ArticleId><ArticleId IdType="pubmed">25287287</ArticleId></ArticleIdList></Reference><Reference><Citation>Batch BC, Hyland K, Svetkey LP. Branch chain amino acids: biomarkers of health and disease. Curr Opin Clin Nutr Metab Care. 2014;17:86&#x2013;89. doi: 10.1097/MCO.0000000000000010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0000000000000010</ArticleId><ArticleId IdType="pubmed">24310057</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Patin F, Madji Hounoum B, et al. Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol 2016. 10.1111/ene.12956.</Citation><ArticleIdList><ArticleId IdType="pubmed">26822316</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji K, Zheng J, Lv J, Xu J, Ji X, Luo Y-B, et al. Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR&#x2013;YY1&#x2013;PGC1&#x3b1; pathway. Free Radic Biol Med. 2015;84:161&#x2013;170. doi: 10.1016/j.freeradbiomed.2015.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.03.020</ArticleId><ArticleId IdType="pubmed">25843656</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J, Cortez C, Gan W-B, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet. 2014;23:1413&#x2013;1424. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau MDL, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A. 2010;107:12553&#x2013;12558. doi: 10.1073/pnas.1006962107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006962107</ArticleId><ArticleId IdType="pmc">PMC2906565</ArticleId><ArticleId IdType="pubmed">20616029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer H, Lang K, Buck E, et al. ALS-causing mutations differentially affect PGC-1&#x3b1; expression and function in the brain vs. peripheral tissues. Neurobiol Dis. 2017;97:36&#x2013;45. doi: 10.1016/j.nbd.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.11.001</ArticleId><ArticleId IdType="pubmed">27818323</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang H, Ward WF, Jang YC, et al. PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve. 2011;44:947&#x2013;956. doi: 10.1002/mus.22217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22217</ArticleId><ArticleId IdType="pubmed">22102466</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Chen S-T, Sun Y, et al. Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer&#x2019;s disease. Redox Biol 2019;22. 10.1016/j.redox.2019.101133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383137</ArticleId><ArticleId IdType="pubmed">30785085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>